Rozlytrek (Entrectinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Rozlytrek is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Rozlytrek is also referred to by its drug name, entrectinib.

Rozlytrek is a member of a class of drugs called kinase inhibitors. Rozlytrek is believed to work by targeting ROS1 fusion proteins. It finds and binds to them inside cancer cells. This blocks the ROS1 fusion proteins from sending signals. Blocking these signals helps to slow or stop the cancer from growing.

How do I take it?
Rozlytrek comes in capsules or pellets, and it is usually taken orally once per day. Your doctor will prescribe a dosage based on your needs. Rozlytrek should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Rozlytrek lists common side effects including tiredness, constipation, change in taste, swelling, dizziness, diarrhea, nausea, abnormal touch sensation, shortness of breath, muscle pain, confusion, mental status changes, memory problems, hallucinations, weight gain, cough, vomiting, fever, joint pain, and vision changes.

Rare but serious side effects listed for Rozlytrek include congestive heart failure, central nervous system effects, bone fractures, liver problems, increased uric acid level in your blood, changes in the electrical activity of your heart called QT prolongation, and vision problems.

For more details about this treatment, visit:

Rozlytrek — Genentech

Rozlytrek — RxList

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in